Abstract: The invention belongs to the technical field of harmonic contribution evaluation, and particularly relates to a system for tracing harmonic sources based on a cloud-edge-terminal collaboration and a method thereof, comprising: terminal module, collecting and transmitting real-time harmonic data to edge module; edge module, comprising plurality of edge computing servers deployed for the transformer substations and the transformer districts by units, realizing hierarchical control between edge computing servers according to voltage levels, and transmitting harmonic sources tracing task through hierarchical interactions between the edge computing servers; the edge computing server receiving harmonic sources tracing service request performs the tracing task, and feeds tracing result back to central module; and, central module, comprising cloud server receiving harmonic sources tracing service request initiated by user, determining edge computing server offloaded by the request, storing final tracing result from e

Abstract: The present invention relates to a specific binding protein targeting PD-L1 and CD73, wherein the specific binding protein is capable of specifically binding to PD-L1 and/or a fragment thereof, and CD73 and/or a fragment thereof. The present invention further relates to use of the specific binding protein in the treatment, prevention and/or diagnosis of diseases such as immune diseases, acute and chronic inflammatory diseases, and tumor diseases.

Abstract: Provided are an antigen binding protein capable of binding to PD-1 and a fusion protein thereof, and corresponding preparation method therefor and the use thereof. The fusion protein is capable of targeting PD-1 and CD73.

Abstract: Provided an isolated antigen binding protein having one or more of the following properties: a. capable of binding to both human CD73 and Cynomolgus monkey CD73; b. capable of inhibiting 5?ectonucleotidase activity of CD73; c. capable of mediating CD73 internalization; d. capable of promoting T cell proliferation; e. with a relatively stable concentration in serum; and f. capable of inhibiting tumor growth and/or tumor cell proliferation. In addition, provided a method for producing the isolated antigen binding protein as well as pharmaceutical uses of the isolated antigen binding protein in preventing, alleviating and/or treating tumor.